Revolutionizing xRNA Production: The Economic Case For Continuous Manufacturing

By Aaron B. Cowley, Ph.D., Chief Scientific Officer

The development of xRNA therapeutics and vaccines is frequently slowed down by high costs and lengthy production timelines. Conventional batch manufacturing, which can take weeks, involves multiple cleanroom suites, increases operational inefficiencies, and makes the highly sensitive RNA molecules susceptible to degradation.

A continuous manufacturing platform is emerging as a critical solution to these pain points. This approach dramatically shortens production from weeks to a matter of days—and soon, potentially under 24 hours—by integrating all critical steps from in vitro transcription to lipid nanoparticle formulation within a single, streamlined process. It maximizes efficiency by reducing required operator time and allowing for the simultaneous production of multiple products. Furthermore, integrating advanced Process Analytical Technology (PAT) tools ensures real-time quality control, which drastically accelerates batch release and process optimization. Discover how this shift to continuous processing is helping accelerate time to clinical trials, lower costs, and expand global patient access.